Drug profile · INN
saxagliptin hydrochloride
SAXAGLIPTIN
saxagliptin hydrochloride (SAXAGLIPTIN) is a dipeptidyl peptidase iv inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — saxagliptin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 3
- Data quality
- 0.89
Quick answer
saxagliptin hydrochloride (SAXAGLIPTIN) is a dipeptidyl peptidase iv inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is saxagliptin hydrochloride?
saxagliptin hydrochloride (SAXAGLIPTIN) is a dipeptidyl peptidase iv inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for saxagliptin hydrochloride?
SAXAGLIPTIN is a marketed brand name for saxagliptin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of saxagliptin hydrochloride?
saxagliptin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.